In Conversation

"In Austria, we will generate higher revenues than in 2016. It has hence been a good year for us"

"Rare diseases affect – in total - a large population. However, individual rare diseases are very heterogeneous and people affected by these as well as their…

"We have the highest coverage of citizens of any country in Europe, which has been highlighted by studies by the OECD and the London School of…

"The time has come for the international community to reevaluate Vienna’s role in the pharmaceuticals and life sciences landscape."

"The private market still has a great potential to grow, thus for us this sector has still a large growth potential in the already well developed…

"Our focus is on further developing our Vienna gateway to support the evolving needs of the CEE region especially in the life sciences logistics area, and…

"Prevention treatment in Austria is not covered as well as it should be. Austrians are programmed to only visit a doctor when they are in pain."

"In Austria, we are in a privileged position to be able to offer orphan drugs to our patients as there exists an open mindset when discussing…

"Vienna can be regarded as a center of excellence for plasma and hematology." Josef Weinberger

"The excellent work that our teams are doing we hope will continue to attract the eyes of headquarters when global R&D allocate their trials."

"Due to my background as a chemist and years in the hospital setting, I saw room for improvement to develop novel innovative blood tests; therefore, ARCHIMEDlife…

"Shire started as a very small company in Austria; therefore, the global move to merge with Baxalta (formerly part of Baxter), which had a huge footprint…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here